Alira Health’s Ventures Portfolio Company, X-COR Therapeutics, Closes Initial $2.6M Funding Round

X-COR’s innovative technology transforms support for patients with respiratory failure and includes COVID-19 treatment applications.

News
Published on:
November 20, 2020

FRAMINGHAM, MASSACHUSETTS – November 12, 2020 – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, congratulates X-COR Therapeutics for closing a $2.6M seed financing to continue developing its novel extracorporeal carbon dioxide removal device for use in clinical trials. Alira Health’s investment arm, Alira Health Ventures, added X-COR Therapeutics in 2019 as a portfolio company and led the recent seed financing with syndication from Good Growth Capital, PiSA Biopharm, Flybridge Partners’ Graduate Syndicate, and other notable angel investors.

“X-COR Therapeutics is continuing to develop its novel filtration system and compatible dialysate strategy for clinical testing and regulatory assessment. Working with the Alira Health Ventures Team generated additional momentum for X-COR to advance development during the COVID-19 pandemic and the addition of Gabriele Brambilla to our board further accelerates our progress,” said Jayon Wang, CEO of X-COR.

“We are pleased with the X-COR Team’s progress through this unprecedented year and are proud to work with such an elite investor group supporting this important technology,” said Gabriele Brambilla, Alira Health’s CEO. “Alira Health Ventures is dedicated to nurturing innovative technologies and propelling development from concept to clinical evaluation for future commercialization. X-COR’s technology will be transformational in the lives of patients suffering from respiratory failure, and this funding is a key milestone in accelerating the development of this vital technology.”

About X-COR Therapeutics:

X-COR Therapeutics is a Boston-based medical device company creating the first commercially available carbon dioxide removal device that uses ultra-low-blood flows for a cheaper, safer, and more accessible treatment for acute respiratory failure. X-COR’s novel technology is a patent-pending medical device and accompanying control algorithm that enables physicians to directly remove excess carbon dioxide from lung failure patients.
To learn more about X-COR, visit http://xcortherapeutics.com/

About Alira Health Ventures:

As part of Alira Health, Alira Health Ventures is an accelerator for an innovative group of portfolio companies positioned to launch the next breakthrough technologies in medical devices and pharmaceuticals. From discovery to commercialization, Alira Health Ventures invests in products that advance healthcare and impact patients’ lives.

Read the press release on Businesswire here.

For more information about Alira Health Ventures

Click here

Related news

Due Diligence Research & Development
Publications August 18, 2021
Infographic: Indication Prioritization and Pre-Commercial Value Assessment
Download our infographic on Indication Prioritization and Pre-Commercial Value Assessment.
Research & Development
Events August 8, 2021
Event: BioProcess International
Join Alira Health at BioProcess International on September 20-23, 2021.
Pharma Research & Development
Publications August 2, 2021
Infographic: Prioritization Strategy of R&D Targets for Biotech Company
Download our infographic on Prioritization Strategy of R&D Targets for Biotech Company
Regulatory
Events July 20, 2021
Webinar Recap: Risk Management & Regulatory Submissions
Download Alira Health's Senior Vice President, Regulatory Affairs, Mary McNamara-Cullinane's webinar presentation, How to Implement Risk Management into Regulatory Submissions Using(...)
Regulatory
Publications July 20, 2021
Infographic: The Pre-IND to Market Approval Roadmap in the U.S.
Download our latest infographic, The Pre-IND to Market Approval Roadmap in the U.S.
Research & Development
Publications June 9, 2021
EU Supply Integrity Guidelines
Check out Alira Health's latest publication, “EU Supply Integrity Guidelines”. In the document, best practices for European distribution and supply integrity management are highlighted(...)
Research & Development
Publications May 27, 2021
Buffers – Navigating New Demands On Downstream Raw Materials
The COVID-19 pandemic has put unusual pressures on the supply and demand of raw materials required for the production and purification of biologics. A specific concern for the biomanufacturing(...)

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.